Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,613.56
(
0.44%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 226604

Friday, 11/01/2019 10:57:54 AM

Friday, November 01, 2019 10:57:54 AM

Post# of 257302
Re: Mavyret sales

ABBV’s new guidance of $3.0B HCV sales for full-year 2019 (given on today’s CC) implies 4Q19 ABBV HCV sales of $703M*. Hence, ABBV does not expect a further decline in HCV sales from 3Q19 to 4Q19.

*ABBV’s HCV sales for the first three quarters of 2019 were $2.297B ($815M + $784M + $698M); $3.0B - $2.297B = $703M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today